Amir Nashat, PhD
Managing Partner, Polaris Venture Partners
Amir Nashat, ScD has served as a member of our board of directors since October 2012. Dr. Nashat is a managing partner at Polaris Partners, a venture capital firm, where he has worked since 2002. Dr. Nashat was also the founding Chief Executive Officer of Living Proof, Inc. and Sun Catalytix Corporation. Dr. Nashat currently represents Polaris as a director of Agbiome, Inc., aTyr Pharmaceuticals, Inc., CAMP4 Therapeutics, Inc., Dewpoint Therapeutics, Inc., Metacrine, Inc., Olivo Laboratories, LLC, Morphic Holding, Inc., Selecta Biosciences, Inc., Syros Pharmaceuticals, Inc., and Taris Holdings LLC. Outside of Polaris, he serves on the BIO Emerging Companies Section Governing Board, the nonprofit Institute for Protein Innovation Board, the Living Proof Advisory Board, the Partners Healthcare Innovation Fund Board, the ALIOTHtalent Board, the Investment Advisory Committee for The Engine at MIT, and helped launch the MIT Sandbox Innovation Fund as its active president. Dr. Nashat received a MS and BS in materials science and mechanical engineering from the University of California, Berkeley and a ScD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under Dr. Robert Langer.
Kristina Burow
Managing Director, ARCH Venture Partners
Kristina Burow has served as a member of our board of directors since August 2014. Ms. Burow has served as Managing Director of ARCH Venture Partners, or ARCH, since November 2011 and previously held roles of increasing responsibility at ARCH from August 2002 to November 2011. Ms. Burow currently serves on the board of directors of several biopharmaceutical companies, including Vividion Therapeutics, Inc., Lycera Corp., Sienna Biopharmaceuticals, Inc., Metacrine, Inc., UNITY Biotechnology, Inc., BEAM Therapeutics., AgBiome Inc., and AgTech Accelerator. She previously was a co-founder and member of the board of directors of Receptos, Inc., (acquired by Celgene Corporation). Ms. Burow has participated in a number of other ARCH portfolio companies including Siluria Technologies, Inc., KYTHERA Biopharmaceuticals, Inc. (acquired by Allergan), and Ikaria, Inc. (acquired by Mallinckrodt). Prior to joining ARCH, Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego and an early employee at the Genomics Institute of the Novartis Research Foundation. Ms. Burow received a BS in Chemistry from the University of California, Berkeley, an MA in Chemistry from Columbia University, and an MBA from the University of Chicago.
Michael Gilman, PhD
CEO, Arrakis Therapeutics
Michael Gilman, PhD, has served as a member of our board of directors since November 2013. Dr. Gilman is currently Chief Executive Officer for Arrakis Therapeutics, Inc., a role he has served in since 2016. He also serves on the Board of Directors of Obsidian Therapeutics, Inc. and Novartis Venture Fund, and on the Scientific Advisory Board of FutuRx, an Israeli biotech accelerator. From October 2016 to April 2019, he served as Chief Executive Officer for Obsidian Therapeutics, Inc. Previously, from 2014 to 2016, Dr. Gilman was Founder and Chief Executive Officer of Padlock Therapeutics, Inc. Prior to Padlock, Dr. Gilman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec Inc. from 2012 to 2013. He joined Biogen Idec Inc. in 2012 following its acquisition of Stromedix, Inc., where he was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, from 1999 to 2005, Dr. Gilman served in a variety of capacities, most recently as Executive Vice President, Research at Biogen Idec. From 1994 to 1999, Dr. Gilman was at ARIAD Pharmaceuticals, Inc., where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Dr. Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York. Dr. Gilman was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a PhD in Biochemistry from University of California, Berkeley, and a SB in life sciences from Massachusetts Institute of Technology.